A61K33/26

MODIFIED CYCLODEXTRIN COATED MAGNETITE NANOPARTICLES FOR TARGETED DELIVERY OF HYDROPHOBIC DRUGS

The invention discloses a composition comprising surface modified iron oxide nanoparticles with citric acid modified cyclodextrin with a hydrodynamic diameter of less than 10 nm and a hydrophobic molecule.

The composition finds use in targeted delivery of a hydrophobic drug and as contrast agent in imaging applications.

MEDICINAL COMPOSITION, BLOOD TREATMENT DEVICE, COSMETIC, FOOD AND DRINK USING COMBUSTION SYNTHESIS MATERIAL
20180008633 · 2018-01-11 ·

Disclosed are a pharmaceutical composition, cosmetic product, and food or drink product each comprising a porous ceramic obtained by combustion synthesis of a starting material comprising (1) titanium and (2) at least one member selected from the group consisting of carbon, boron, nitrogen, and silicon; a pharmaceutical composition and cosmetic product each comprising a radical- and nanobubble-containing liquid; and a blood treatment device comprising a blood flow channel for extracorporeal circulation of a patient's blood, the blood flow channel being provided with the porous ceramic above, and the porous ceramic and the blood are brought into contact with each other.

BIOCOMPATIBLE PHOTOTHERMAL COMPOSITION FOR TREATMENT OF CANCER AND SKIN DISEASES

The present invention relates to a biocompatible photothermal composition that can be used in various fields including the treatment of cancer and skin diseases.

BIOCOMPATIBLE PHOTOTHERMAL COMPOSITION FOR TREATMENT OF CANCER AND SKIN DISEASES

The present invention relates to a biocompatible photothermal composition that can be used in various fields including the treatment of cancer and skin diseases.

COMPOSITIONS AND METHODS WITH A PROBIOTIC AND A N-3 FATTY ACID FOR THE PREVENTION OR TREATMENT OF MASTITIS
20230000931 · 2023-01-05 ·

The invention provide a mix or a nutritional compostion comprising a probiotic Lactobacillus Fermentum CECT-5716 and a n-3 fatty acid selected from the group consisting of docosahexaenoic acid (DHA) and 18:3 n-3 octadecatrienoic acid (alpha-linolenic acid); and optional a further nutrient or mineral selected from the group consisting of iron, manganese and magnesium, or combination of two of more thereof; for use in treating or preventing mastitis in a subject, preferably a pregnant or lactating woman.

COMPOSITIONS AND METHODS WITH A PROBIOTIC AND A N-3 FATTY ACID FOR THE PREVENTION OR TREATMENT OF MASTITIS
20230000931 · 2023-01-05 ·

The invention provide a mix or a nutritional compostion comprising a probiotic Lactobacillus Fermentum CECT-5716 and a n-3 fatty acid selected from the group consisting of docosahexaenoic acid (DHA) and 18:3 n-3 octadecatrienoic acid (alpha-linolenic acid); and optional a further nutrient or mineral selected from the group consisting of iron, manganese and magnesium, or combination of two of more thereof; for use in treating or preventing mastitis in a subject, preferably a pregnant or lactating woman.

COMPOSITIONS AND METHODS WITH A PROBIOTIC AND A N-3 FATTY ACID FOR THE PREVENTION OR TREATMENT OF MASTITIS
20230000931 · 2023-01-05 ·

The invention provide a mix or a nutritional compostion comprising a probiotic Lactobacillus Fermentum CECT-5716 and a n-3 fatty acid selected from the group consisting of docosahexaenoic acid (DHA) and 18:3 n-3 octadecatrienoic acid (alpha-linolenic acid); and optional a further nutrient or mineral selected from the group consisting of iron, manganese and magnesium, or combination of two of more thereof; for use in treating or preventing mastitis in a subject, preferably a pregnant or lactating woman.

NUTRACEUTICAL OR PHARMACEUTICAL COMPOSITION COMPRISING IRON PYROPHOSPHATE FOR TREATING AND/OR PREVENTING IRON DEFICIENCY CONDITIONS OR DISEASES
20230000907 · 2023-01-05 ·

Provided herein is a composition of substances preferably obtained from natural sources, which is effective in preventing and/or treating iron deficiency conditions or diseases. The composition includes iron pyrophosphate, phosphatidylserine, phosphatidylcholine and starch, preferably acetylated pregelatinised starch. The formulation gives the composition gastro-resistance properties and high bioavailability of the active ingredient iron pyrophosphate. The composition is prepared in the form of a solid, semi-solid or liquid pharmaceutical dosage, preferably for oral administration.

NUTRACEUTICAL OR PHARMACEUTICAL COMPOSITION COMPRISING IRON PYROPHOSPHATE FOR TREATING AND/OR PREVENTING IRON DEFICIENCY CONDITIONS OR DISEASES
20230000907 · 2023-01-05 ·

Provided herein is a composition of substances preferably obtained from natural sources, which is effective in preventing and/or treating iron deficiency conditions or diseases. The composition includes iron pyrophosphate, phosphatidylserine, phosphatidylcholine and starch, preferably acetylated pregelatinised starch. The formulation gives the composition gastro-resistance properties and high bioavailability of the active ingredient iron pyrophosphate. The composition is prepared in the form of a solid, semi-solid or liquid pharmaceutical dosage, preferably for oral administration.

NUTRACEUTICAL OR PHARMACEUTICAL COMPOSITION COMPRISING IRON PYROPHOSPHATE FOR TREATING AND/OR PREVENTING IRON DEFICIENCY CONDITIONS OR DISEASES
20230000907 · 2023-01-05 ·

Provided herein is a composition of substances preferably obtained from natural sources, which is effective in preventing and/or treating iron deficiency conditions or diseases. The composition includes iron pyrophosphate, phosphatidylserine, phosphatidylcholine and starch, preferably acetylated pregelatinised starch. The formulation gives the composition gastro-resistance properties and high bioavailability of the active ingredient iron pyrophosphate. The composition is prepared in the form of a solid, semi-solid or liquid pharmaceutical dosage, preferably for oral administration.